Advances in the development of thrombin inhibitors

Expert Opinion on Investigational Drugs
T SteinmetzerJ Stürzebecher

Abstract

Thromboembolic diseases are a major cause of morbidity and mortality, particularly in the Western world, which has stimulated enormous research efforts by the pharmaceutical industry to introduce new antithrombotic therapies. One strategy is the development of direct inhibitors of the serine protease thrombin, which holds a central position in the final steps of the blood coagulation cascade and in platelet activation. At present there is only limited clinical use of some parenteral preparations of thrombin inhibitors in acute situations, especially when the common antithrombotic drugs heparin, warfarin and aspirin are ineffective or associated with side effects. However, for use in prophylaxis of thrombotic diseases such inhibitors should be orally available, must be safe to avoid bleeding complications and should have an appropriate half-life, allowing once or twice daily dosing to maintain adequate antithrombotically effective blood levels. Details of several new and potent thrombin inhibitors have been published during the last years. For some of them oral bioavailability is claimed and they are effective in in vitro coagulation assays. However, most of them showed only limited efficacy in animal studies with respect to the...Continue Reading

References

Jan 1, 1979·Thrombosis Research·C Kettner, E Shaw
Oct 1, 1978·International Journal of Peptide and Protein Research·S BajuszD Bagdy
Jan 1, 1993·Advances in Experimental Medicine and Biology·S ElgendyG Claeson
Jan 1, 1997·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·B E LewisY Rangel
Jan 1, 1999·Bioorganic & Medicinal Chemistry Letters·P E SandersonJ P Vacca
Jan 1, 1999·Bioorganic & Medicinal Chemistry Letters·Y S OhS Kim
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·K LeeD S Kim
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·K LeeY J Yoo
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·J S PlummerP D Winocour
Feb 6, 1999·Bioorganic & Medicinal Chemistry Letters·J E SempleT K Brunck
Feb 6, 1999·Bioorganic & Medicinal Chemistry Letters·J AmblerM Tweed
Mar 13, 1999·Thrombosis Research·J Hauptmann, J Stürzebecher
Mar 26, 1999·Bioorganic & Medicinal Chemistry Letters·M PassC Patel
Apr 14, 1999·Bioorganic & Medicinal Chemistry Letters·J B RewinkelC A van Boeckel
Apr 14, 1999·Bioorganic & Medicinal Chemistry Letters·J AmblerM Tweed
Apr 17, 1999·Bioorganic & Medicinal Chemistry Letters·J S PlummerP Winocour
Apr 27, 1999·Journal of Computer-aided Molecular Design·R Bursi, P D Grootenhuis
Jul 9, 1999·Bioorganic & Medicinal Chemistry Letters·M PassC Patel
Jul 22, 1999·European Heart Journal·M Oberhoff, K R Karsch

❮ Previous
Next ❯

Citations

May 14, 2005·European Journal of Medicinal Chemistry·Andreja KranjcDanijel Kikelj
Apr 24, 2012·Chemical Reviews·Reem SmoumMorris Srebnik
Aug 3, 2004·Nature Reviews. Drug Discovery·David GustafssonAnn-Catrine Teger-Nilsson
Jun 7, 2005·Proceedings of the National Academy of Sciences of the United States of America·Daniel RiesterAndreas Schwienhorst
Jan 3, 2006·Proceedings of the National Academy of Sciences of the United States of America·Ariel FernándezR Stephen Berry
Mar 1, 2006·Proceedings of the National Academy of Sciences of the United States of America·Nicholas R Cozzarelli
Apr 22, 2005·Journal of Biomolecular Structure & Dynamics·Ariel FernándezBob Jernigan
Jun 27, 2012·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Elena I SinauridzeFazoil I Ataullakhanov
Feb 5, 2005·Pathophysiology of Haemostasis and Thrombosis·Danijel Kikelj
Apr 2, 2002·Expert Opinion on Investigational Drugs·Mats ErikssonAnders Larsson
Aug 29, 2009·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·Juan Pablo Ordovás BainesIsabel Valero García
Aug 14, 2009·Bioorganic & Medicinal Chemistry Letters·Stephen HanessianOla Fjellström
May 19, 2009·Bioorganic & Medicinal Chemistry Letters·Guijun WangBranden Hopkinson
Jul 23, 2008·Bioorganic & Medicinal Chemistry Letters·Stephen P O'ConnorYing Wang
Feb 22, 2008·Bioorganic & Medicinal Chemistry Letters·Stephen HanessianOla Fjellström
Oct 24, 2007·European Journal of Medicinal Chemistry·Rainer FriedrichWolfram Bode
Apr 11, 2007·Bioorganic & Medicinal Chemistry Letters·Robert J YoungPing Zhou
Feb 8, 2006·Bioorganic & Medicinal Chemistry Letters·Udo E W LangeH Wolfgang Höffken
Nov 18, 2005·Bioorganic & Medicinal Chemistry Letters·Stephen HanessianYafeng Xue
Jan 27, 2004·The Annals of Pharmacotherapy·Edith A Nutescu, Ann K Wittkowsky
Sep 25, 2002·Bioorganic & Medicinal Chemistry Letters·Stephen HanessianIngemar Nilsson
Nov 21, 2007·Organic & Biomolecular Chemistry·David BlombergJan Kihlberg
Sep 1, 2012·Pharmaceutical Patent Analyst·Anilkumar R Kore, Muthian Shanmugasundaram
Mar 31, 2004·European Journal of Medicinal Chemistry·Petra MarinkoDanijel Kikelj
Aug 10, 2006·Journal of the American Chemical Society·Stephen HanessianNiklas Blomberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Nature Structural & Molecular Biology
Raymond C Stevens
Haemophilia : the Official Journal of the World Federation of Hemophilia
P A Fields, K J Pasi
© 2021 Meta ULC. All rights reserved